产品说明书

Ribostamycin Sulfate

Print
Chemical Structure| 53797-35-6 同义名 : Vistamycin sulfate
CAS号 : 53797-35-6
货号 : A391931
分子式 : C17H36N4O14S
纯度 : 98%
分子量 : 552.551
MDL号 : MFCD23380549
存储条件:

粉末 Inert atmosphere,2-8°C

液体 -20°C:3-6个月-80°C:12个月

溶解度 :

H2O: 120 mg/mL(217.17 mM),配合低频超声助溶

动物实验配方:
生物活性
描述 Ribostamycin Sulfate is a broad-spectrum antimicrobial, inhibits bacterial protein synthesis at the level of 30S and 50S ribosomal subunit binding. The binding affinity of ribostamycin to purified bovine PDI (protein disulfide isomerase) was 319 μM (K(D) value)[3]. Moreover, MIC(90) of ribostamycin is 32 mg/L)[4]. The linear relationship of ribostamycin sulfate and kanamycin between concentration and peak height was obtained in the concentration range of 0.18-1.08 mM and 0.31-1.86 mM and the determination limit was 7. 2 nM and 46 nM respectively[5]. The Cmax in children and infants after intramuscular ribostamycin 10 mg/kg approached that in adults after an intramuscular dose of ribostamycin 500 mg. It is suggested that ribostamycin was administered in intramuscular doses of 10 to 15 mg/kg twice daily in infants and 3 times daily in children, respectively[6].
实验方案
1mg 5mg 10mg

1 mM

5 mM

10 mM

1.81mL

0.36mL

0.18mL

9.05mL

1.81mL

0.90mL

18.10mL

3.62mL

1.81mL

参考文献

[1]Horibe T, Nagai H, et al. Ribostamycin inhibits the chaperone activity of protein disulfide isomerase. Biochem Biophys Res Commun. 2001 Dec 21;289(5):967-72.

[2]Hunfeld KP, Weigand J, et al. In vitro activity of mezlocillin, meropenem, aztreonam, vancomycin, teicoplanin, ribostamycin and fusidic acid against Borrelia burgdorferi. Int J Antimicrob Agents. 2001 Mar;17(3):203-8.

[3] Horibe T, Nagai H, Sakakibara K, Hagiwara Y, Kikuchi M. Ribostamycin inhibits the chaperone activity of protein disulfide isomerase. Biochem Biophys Res Commun. 2001;289(5):967‐972.

[4]Hunfeld KP, Weigand J, Wichelhaus TA, Kekoukh E, Kraiczy P, Brade V. In vitro activity of mezlocillin, meropenem, aztreonam, vancomycin, teicoplanin, ribostamycin and fusidic acid against Borrelia burgdorferi. Int J Antimicrob Agents. 2001;17(3):203‐208.

[5]Liang YA, Zhang TM. Yao Xue Xue Bao. 1992;27(2):157‐160.

[6]Zhou SL, Shen G, Zhong HF. Pharmacokinetics of ribostamycin in paediatric patients. Clin Pharmacokinet. 1992;22(2):144‐151.